SCHEMBL9334907

SCHEMBL9334907

N=C(NN)NOCC[C@H](N)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 2/20 0.39
SLC1A1 P43005 2/20 0.39
GRM8 O00222 1/20 0.39
GRM6 O15303 1/20 0.39
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
CYP1A2 P05177 1/20 0.39
GRIK1 P39086 1/20 0.39
GRM5 P41594 1/20 0.39
GRIA1 P42261 1/20 0.39
GRIA2 P42262 1/20 0.39
GRIA3 P42263 1/20 0.39
SLC1A3 P43003 1/20 0.39
SLC1A2 P43004 1/20 0.39
GRIA4 P48058 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2A Q12879 1/20 0.39
GRIK2 Q13002 1/20 0.39
GRIK3 Q13003 1/20 0.39
GRIN2B Q13224 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Canavanine SCHEMBL2579370 0.81 PMP22 (0.45) GSRSLC1A1GRM8GRM6GRIN2D
Canavanine SCHEMBL151097 0.81 PMP22 (0.45) GSRSLC1A1GRM8GRM6GRIN2D
Canavanine SCHEMBL151096 0.81 PMP22 (0.45) GSRSLC1A1GRM8GRM6GRIN2D
SCHEMBL28605005 0.80 NOS3 (0.46) GSRSLC1A1GRM8GRM6GRIN2D
SCHEMBL21114398 0.80 NOS3 (0.46) GSRSLC1A1GRM8GRM6GRIN2D
Canavanine SCHEMBL3920895 0.80 PMP22 (0.44) GSRSLC1A1GRM8GRM6GRIN2D
SCHEMBL16681576 0.80 GSR (0.41) GSRSLC1A1GRM8GRM6GRIN2D
SCHEMBL17797937 0.79 GSR (0.46) GSRSLC1A1GRM8GRM6GRIN2D
Canavanine SCHEMBL6885261 0.79 PMP22 (0.42) GSRSLC1A1GRM8GRM6GRIN2D
Canavanine SCHEMBL6885258 0.79 PMP22 (0.42) GSRSLC1A1GRM8GRM6GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5318992-A Administering for the treatment of hypotensive conditions and shock MERRELL DOW PHARMACEUTICALS INC. (US) 1994-06-07 US disclosed